Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 4Thoracic 2Gastrointestinal 2Tumor-Agnostic 1Sarcoma 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Neoplasms 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Nivolumab 24pembrolizumab 22Ipilimumab 17Specimen Handling 15Magnetic Resonance Spectroscopy 9CTLA-4 Antigen 8Opdualag 7relatlimab 6Cyclophosphamide 6binimetinib 5Paclitaxel 5trametinib 4fludarabine phosphate 4fludarabine 4cemiplimab 4Carboplatin 4Biopsy 4lifileucel 3dabrafenib 3atezolizumab 3X-Rays 3Taxes 3Standard of Care 3Radiotherapy 3Radiation 3Pemetrexed 3Introns 3Interferon alpha-2 3Immunoglobulin G 3Gemcitabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
AZD 6244 × Dermatologic × 30 days × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡